Project Grant R44HL132721

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Parmedics, Inc., a for-profit, woman-owned biotechnology company, for the development of small molecule protease-activated receptor-2 (PAR2) antagonists as potential oral therapeutics for asthma. The goal is to characterize two novel PAR2 antagonists, C937 and C938, with improved pharmacodynamics and pharmacokinetics to enable...

This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $320,863 to Aaiit LLC (Inflammation Immuno Therapy) to develop a bifunctional IgE antagonist and dissociator (ANDI) drug to treat severe allergic asthma. The ANDI drug aims to directly access and dissociate IgE bound to mast cell receptors, in contrast to the first-generation Xolair drug which only...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...

This federal Project Grant award of $231,617 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Davis to investigate the efficacy of inhaled pitavastatin as a novel therapy for the treatment of asthma. The key objectives are to: 1) determine the efficacy of inhaled pitavastatin as a bronchodilator in a rhesus macaque model of airway hyperresponsiveness, and 2) evaluate the...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $207,500 to the University of Southern California to study the role of the MIF/CD74 pathway in group 2 innate lymphoid cells (ILC2) and its impact on airway hyperreactivity and asthma. The key objectives of this 2-year research project are to: 1) Assess the expression patterns of CD74 in the lungs and measure...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $262,098 to the University of Wisconsin - Madison to develop and characterize human induced pluripotent stem cell (iPSC)-derived neutrophil therapies against pathogenic Aspergillus fungi. The key objectives are to assess the ability of iPSC-derived neutrophils to inhibit the growth of the two most common causative agents...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Cellergy Pharma Inc. to develop a bispecific antibody therapy that can efficiently and specifically eliminate IgE-producing B cells without significant side effects. The goal is to achieve complete and durable suppression of allergic symptoms for severe allergic diseases affecting millions of...

This Project Grant award of $1,491,931 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research is focused on investigating the immune mechanisms by which GLP-1 receptor agonists can reduce inflammation in both lean and obese patients with asthma. The research aims to identify the cellular targets and anti-inflammatory pathways of GLP-1 signaling in order to inform the clinical repurposing of GLP-1R agonists for asthma...